Asset Details
Do you wish to reserve the book?
Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment
Do you wish to request the book?
Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment
2022
Overview
Soluble immune checkpoint molecules are emerging novel mediators of immune regulation. However, it is unclear whether soluble immune checkpoint proteins affect the development of hepatocellular carcinoma (HCC) during nucleos(t)ide analogue (NA) treatment in patients with chronic hepatitis B virus infection. This study included 122 NA-naïve patients who received NA therapy. We assessed the associations of clinical factors, including soluble immune checkpoint proteins, with HCC development during NA treatment. The baseline serum concentrations of 16 soluble immune checkpoint proteins were measured using multiplexed fluorescent bead-based immunoassay. In total, 13 patients developed HCC during the follow-up period (median duration, 4.3 years). Of the 16 proteins, soluble inducible T-cell co-stimulator (≥ 164.71 pg/mL;
p
= 0.014), soluble programmed cell death-1 (sPD-1) (≤ 447.27 pg/mL;
p
= 0.031), soluble CD40 (≤ 493.68 pg/mL;
p
= 0.032), and soluble herpes virus entry mediator (≤ 2470.83 pg/mL;
p
= 0.038) were significantly associated with HCC development (log-rank test). In multivariate analysis, an sPD-1 level ≤ 447.27 pg/mL (
p
= 0.014; hazard ratio [HR], 4.537) and α-fetoprotein level ≥ 6.4 ng/mL (
p
= 0.040; HR, 5.524) were independently and significantly associated with HCC development. Pre-treatment sPD-1 is a novel predictive biomarker for HCC development during NA treatment.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ Antiviral Agents - therapeutic use
/ Carcinoma, Hepatocellular - diagnostic imaging
/ Carcinoma, Hepatocellular - prevention & control
/ Carcinoma, Hepatocellular - virology
/ Female
/ Guanine - analogs & derivatives
/ Hepatitis B, Chronic - blood
/ Hepatitis B, Chronic - diagnosis
/ Hepatitis B, Chronic - drug therapy
/ Hepatitis B, Chronic - virology
/ Humanities and Social Sciences
/ Humans
/ Liver Neoplasms - diagnostic imaging
/ Liver Neoplasms - prevention & control
/ Male
/ Nucleosides - therapeutic use
/ Patients
/ Programmed Cell Death 1 Receptor - blood
/ Proteins
/ Science
